Asset profile
PB-119
Peptide
Evidence outlook · lead readout
NCT04504396 · Type 2 Diabetes Mellitus (T2DM)
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT04504396: This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint, change in HbA1c, was clearly met, with PB-119 producing a significantly larger reduction than placebo (P<0.001).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
110 competitors in this universe: 24 direct rivals (same mechanism and indication), 26 same-class, 60 same-indication; 34 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| PB-119: this drug | Phase 3 | Peptide | GLP-1 receptor | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lixisenatide (Adlyxin / Lyxumia) | Approved | Peptide | GLP-1 receptor | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| CJC-1134-PC | Phase 3 | Peptide | GLP-1 receptor | ||
| Efpeglenatide | Phase 3 | Peptide | GLP-1 receptor | ||
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Exendin-4 Fc Fusion (JY09) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | ||
| HDG1901 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HRS-7535 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HSK7653 | Phase 3 | Small molecule | GLP-1 receptor |
…and 95 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
18 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.